- Home
- PMF vs CRDF Comparison
PMF vs CRDF Comparison
Compare PMF & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMF
- CRDF
- Stock Information
- Founded
- PMF 2001
- CRDF 1999
- Country
- PMF United States
- CRDF United States
- Employees
- PMF N/A
- CRDF N/A
- Industry
- PMF Finance/Investors Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PMF Finance
- CRDF Health Care
- Exchange
- PMF Nasdaq
- CRDF Nasdaq
- Market Cap
- PMF 209.2M
- CRDF 233.5M
- IPO Year
- PMF N/A
- CRDF N/A
- Fundamental
- Price
- PMF $7.68
- CRDF $4.37
- Analyst Decision
- PMF
- CRDF Strong Buy
- Analyst Count
- PMF 0
- CRDF 6
- Target Price
- PMF N/A
- CRDF $11.92
- AVG Volume (30 Days)
- PMF 61.3K
- CRDF 1.4M
- Earning Date
- PMF 01-01-0001
- CRDF 08-07-2025
- Dividend Yield
- PMF 5.36%
- CRDF N/A
- EPS Growth
- PMF N/A
- CRDF N/A
- EPS
- PMF N/A
- CRDF N/A
- Revenue
- PMF N/A
- CRDF $587,000.00
- Revenue This Year
- PMF N/A
- CRDF N/A
- Revenue Next Year
- PMF N/A
- CRDF N/A
- P/E Ratio
- PMF N/A
- CRDF N/A
- Revenue Growth
- PMF N/A
- CRDF N/A
- 52 Week Low
- PMF $7.69
- CRDF $2.01
- 52 Week High
- PMF $10.56
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- PMF 31.95
- CRDF 72.91
- Support Level
- PMF $7.70
- CRDF $3.07
- Resistance Level
- PMF $7.92
- CRDF $4.55
- Average True Range (ATR)
- PMF 0.07
- CRDF 0.22
- MACD
- PMF -0.02
- CRDF 0.08
- Stochastic Oscillator
- PMF 9.42
- CRDF 94.59
About PMF PIMCO Municipal Income Fund
PIMCO Municipal Income Fund is a closed-end management investment company. Its primary investment objective is to seek to provide current income exempt from federal income tax. The fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal income tax.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.